Diagnostic Medical Systems is France's company engaged in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group’s activity is organized around two sectors: Radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; and the Development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine.
1993
146
LTM Revenue $56.4M
LTM EBITDA $4.2M
$42.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diagnostic Medical has a last 12-month revenue (LTM) of $56.4M and a last 12-month EBITDA of $4.2M.
In the most recent fiscal year, Diagnostic Medical achieved revenue of $51.7M and an EBITDA of $0.8M.
Diagnostic Medical expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Diagnostic Medical valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $56.4M | XXX | $51.7M | XXX | XXX | XXX |
Gross Profit | $56.4M | XXX | $20.7M | XXX | XXX | XXX |
Gross Margin | 100% | XXX | 40% | XXX | XXX | XXX |
EBITDA | $4.2M | XXX | $0.8M | XXX | XXX | XXX |
EBITDA Margin | 8% | XXX | 2% | XXX | XXX | XXX |
EBIT | $0.4M | XXX | -$1.5M | XXX | XXX | XXX |
EBIT Margin | 1% | XXX | -3% | XXX | XXX | XXX |
Net Profit | -$1.2M | XXX | -$3.2M | XXX | XXX | XXX |
Net Margin | -2% | XXX | -6% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $11.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Diagnostic Medical's stock price is EUR 1 (or $1).
Diagnostic Medical has current market cap of EUR 23.7M (or $26.7M), and EV of EUR 37.8M (or $42.4M).
See Diagnostic Medical trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$42.4M | $26.7M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Diagnostic Medical has market cap of $26.7M and EV of $42.4M.
Diagnostic Medical's trades at 0.8x EV/Revenue multiple, and 53.8x EV/EBITDA.
Equity research analysts estimate Diagnostic Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diagnostic Medical has a P/E ratio of -22.0x.
See valuation multiples for Diagnostic Medical and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $26.7M | XXX | $26.7M | XXX | XXX | XXX |
EV (current) | $42.4M | XXX | $42.4M | XXX | XXX | XXX |
EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
EV/EBITDA | 10.0x | XXX | 53.8x | XXX | XXX | XXX |
EV/EBIT | 104.3x | XXX | -28.6x | XXX | XXX | XXX |
EV/Gross Profit | 0.8x | XXX | n/a | XXX | XXX | XXX |
P/E | -22.0x | XXX | -8.2x | XXX | XXX | XXX |
EV/FCF | -20.9x | XXX | 1258.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiagnostic Medical's last 12 month revenue growth is 16%
Diagnostic Medical's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Diagnostic Medical's rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diagnostic Medical's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Diagnostic Medical and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 16% | XXX | 15% | XXX | XXX | XXX |
EBITDA Margin | 8% | XXX | 2% | XXX | XXX | XXX |
EBITDA Growth | 50% | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | 4% | XXX | 17% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagnostic Medical acquired XXX companies to date.
Last acquisition by Diagnostic Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Diagnostic Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was Diagnostic Medical founded? | Diagnostic Medical was founded in 1993. |
Where is Diagnostic Medical headquartered? | Diagnostic Medical is headquartered in France. |
How many employees does Diagnostic Medical have? | As of today, Diagnostic Medical has 146 employees. |
Is Diagnostic Medical publicy listed? | Yes, Diagnostic Medical is a public company listed on PAR. |
What is the stock symbol of Diagnostic Medical? | Diagnostic Medical trades under ALDMS ticker. |
When did Diagnostic Medical go public? | Diagnostic Medical went public in 1998. |
Who are competitors of Diagnostic Medical? | Similar companies to Diagnostic Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
What is the current market cap of Diagnostic Medical? | Diagnostic Medical's current market cap is $26.7M |
What is the current revenue of Diagnostic Medical? | Diagnostic Medical's last 12 months revenue is $56.4M. |
What is the current revenue growth of Diagnostic Medical? | Diagnostic Medical revenue growth (NTM/LTM) is 16%. |
What is the current EV/Revenue multiple of Diagnostic Medical? | Current revenue multiple of Diagnostic Medical is 0.8x. |
Is Diagnostic Medical profitable? | Yes, Diagnostic Medical is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Diagnostic Medical? | Diagnostic Medical's last 12 months EBITDA is $4.2M. |
What is Diagnostic Medical's EBITDA margin? | Diagnostic Medical's last 12 months EBITDA margin is 8%. |
What is the current EV/EBITDA multiple of Diagnostic Medical? | Current EBITDA multiple of Diagnostic Medical is 10.0x. |
What is the current FCF of Diagnostic Medical? | Diagnostic Medical's last 12 months FCF is -$2.0M. |
What is Diagnostic Medical's FCF margin? | Diagnostic Medical's last 12 months FCF margin is -4%. |
What is the current EV/FCF multiple of Diagnostic Medical? | Current FCF multiple of Diagnostic Medical is -20.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.